Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Sarcoma 1Penile Neoplasms 1PD-L1 Positive Mutation Tumor 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Chronic-Phase 1Hodgkin Disease 1Hemangiosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Temozolomide 44Radiotherapy 16Bevacizumab 9Surgical Procedures, Operative 5Carmustine 5pembrolizumab 4Lomustine 4Drug Therapy 4Sunitinib 3Standard of Care 3Radiation 3Procarbazine 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3Chlorotoxin 3Carboplatin 3Blood Specimen Collection 3tislelizumab 2fludarabine 2camrelizumab 2Radiosurgery 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Hyperbaric Oxygenation 2Ethanol 2Cyclophosphamide 2Chemotherapy, Adjuvant 2CT-322 2Bortezomib 2Aminolevulinic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Glioblastoma × avelumab × Clear all
NCT03750071 2022-10-20

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Vaximm GmbH

Phase 1/2 Unknown
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡